Belantamab mafodotin
Belantamab mafodotin (Blenrep, GlaxoSmithKline Trading Services Limited) has 2 EU-approved indications in 1 tumour type.
| Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|
| Multiple myeloma2 | |||
None | + bortezomib and dexamethasone | 2L | After at least one prior therapy; Relapsed or refractory |
None | + pomalidomide and dexamethasone | 2L | After at least one prior therapy including lenalidomide; Relapsed or refractory |
Full text of section 4.1 (therapeutic indications)
Blenrep is indicated in adults for the treatment of relapsed or refractory multiple myeloma: • in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy; and • in combination with pomalidomide and dexamethasone in patients who have received at least one prior therapy including lenalidomide.
Label history
4 changes to the Blenrep label since 2025, none of them to the indications. Newest first, in the words of EMA's record of each procedure.
Changes